Pharmaceutical News

RSS

Probiotic before radiation therapy can protect intestine from damage

Scientists at Washington University School of Medicine in St. Louis have shown that taking a probiotic before radiation therapy can protect the intestine from damage — at least in mice.

17 Nov 2011

Male breast cancer patients report tamoxifen side effects

About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which prompts more than 20 percent of them to discontinue treatment, according to researchers at The University of Texas MD Anderson Cancer Center.

17 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

WSU researchers to study novel antibiotic that may treat VRE infection

The bacteria Enterococcus can cause infections that typically target the digestive tract or bowel; if the bacteria spread, an abdominal abscess or urinary infection could result. Enterococcus also can invade the bloodstream, leading to meningitis, pneumonia or endocarditis - an infection of the heart valve.

17 Nov 2011

Mannosides show promise against urinary tract infections

An experimental treatment for urinary tract infections has easily passed its first test in animals, alleviating weeks-long infections in mice in as little as six hours.

17 Nov 2011

Multivitamin use linked to less healthy behaviors

The lack of evidence on multivitamin health benefits is no impediment to their widespread popularity, with over half the U.S. population popping such pills. This translates into a $27 billion industry, which lures consumers with the illusory promise of better health. But shocking new research suggests taking multivitamins might have the opposite effect -- not simply on the metabolic level, but on a metaphysical one: promoting a false sense of invulnerability that actually leads users to engage in riskier behaviors.

17 Nov 2011

Malawi government addressing drug, medical supply shortages in wake of aid withdrawals

As international donors "remain reluctant to release aid meant for the health sector" in Malawi "amid allegations of pilfering and corruption in the procurement of drugs," "patients seeking medical treatment at government-run medical facilities are unable to access medication such as antiretrovirals (ARVs), anti-malarial drugs and even painkillers," Inter Press Service reports, adding, "Health facilities are also experiencing a shortage of medical equipment such as gloves, and malaria and HIV/AIDS testing kits."

17 Nov 2011

People with prior stroke or diabetes benefit from thrombolytic therapy

People with a history of stroke or diabetes who were given clot-busting drugs to break up blood clots after stroke fared better than those who did not receive the drugs, according to a study published in the November 16, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

17 Nov 2011

Dipyrone may reduce brain damage after stroke

An older nonsteroidal anti-inflammatory drug (NSAID) called dipyrone may offer a new approach to reducing injury to brain tissue after a stroke, according to a study in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

Excessive vitamin D levels can lead to onset of AF

While previous studies have linked vitamin D deficiency to an increased risk for cardiovascular disease, new research at the Intermountain Medical Center Heart Institute shows that too much vitamin D can lead to the onset of a dangerous heart condition known as atrial fibrillation.

16 Nov 2011

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapy for cancer, announced the presentation today of new preclinical data on the development of a miRNA-based therapeutic candidate for primary liver cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

16 Nov 2011

Cholesterol drugs clash head on

Major cholesterol lowering drugs are being pitched against each other. The cheaper ones are more likely to win say experts.

16 Nov 2011

Geron bows out of stem cell research

Geron Corp. is removing itself from the field it pioneered – stem cell research. Late Monday, the company said it would halt its study of a stem cell-based treatment for spinal cord injury, the first embryonic stem cell trial approved in the U.S.

16 Nov 2011

Atherosclerotic plaques spread downstream in coronary arteries

In human coronary arteries, atherosclerotic plaques tend to spread downstream because of the changes in blood flow patterns the plaque causes, researchers have found.

16 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011